4-Chloropyrimidine → N-ethyl-6-(4-pyrimidin-4-yl-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl)-1H-imidazo[4,5-b]pyridin-2-amine
Reaktionsgleichung
[NH2:1][C:2]1[N:7]=[CH:6][C:5]([C:8]2[CH:9]=[CH:10][C:11]3[O:17][CH2:16][CH2:15][N:14]([C:18](OC(C)(C)C)=O)[CH2:13][C:12]=3[CH:25]=2)=[CH:4][C:3]=1[N+:26]([O-])=O.ClC1[CH:35]=[CH:34][N:33]=[CH:32][N:31]=1>>[CH2:6]([NH:7][C:2]1[NH:26][C:3]2[C:2]([N:1]=1)=[N:7][CH:6]=[C:5]([C:8]1[CH:9]=[CH:10][C:11]3[O:17][CH2:16][CH2:15][N:14]([C:18]4[CH:35]=[CH:34][N:33]=[CH:32][N:31]=4)[CH2:13][C:12]=3[CH:25]=1)[CH:4]=2)[CH3:5]Komponenten
3
Versuchsvorschrift
Prepared as an acetate salt according to the method of example 11 by using tert-butyl 7-(6-amino-5-nitropyridin-3-yl)-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate (Example 26) in step 1 and 4-chloropyrimidine in step 4. 1H NMR (400 MHz, DMSO-D6-d6) δ 8.13-8.06 (m, 1H), 7.61 (d, 1H), 7.45-7.41 (m, 2H), 7.37-7.30 (m, 2H), 7.19-7.12 (m, 2H), 6.98 (d, 1H), 6.68-6.62 (m, 1H), 5.05 (s, 2H), 4.43 (d, 2H), 4.20 (d, 2H), 3.35-3.28 (m, 2H), 2.46 (s, 3H), 1.89 (s, 4H), 1.18 (t, 3H); MS (EI) for C21H21N7O: 388 (MH+).